Peptide Library

FDA-approved

Hormones & metabolism

Pramlintide

Evidence

FDA approved

Class

Amylin analog

/

Pramlintide

KEY TAKEAWAY

Pramlintide is a 37-amino-acid synthetic analog of amylin, a hormone released with insulin after meals. It is sold as Symlin. The FDA approved pramlintide (Symlin) in 2005 as an add-on to mealtime insulin.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Amylin analog

Approved for

Type 1 and type 2 diabetes in people who use mealtime insulin

Key fact

The FDA approved pramlintide (Symlin) in 2005 as an add-on to mealtime insulin.

Route

Subcutaneous injection before meals

Evidence strength

FDA approved

What it is

What it is

Pramlintide is a 37-amino-acid synthetic analog of amylin, a hormone released with insulin after meals. It is sold as Symlin.

How it works

How it works

It slows stomach emptying, reduces the release of glucagon after meals and increases fullness.

Regulatory status

Regulatory status

The FDA approved pramlintide (Symlin) in 2005 as an add-on to mealtime insulin.

What it is used for

What it is used for

Type 1 and type 2 diabetes in people who use mealtime insulin.

Side effects and risks

Side effects and risks

Severe low blood sugar is a boxed-warning risk when it is used with insulin. Nausea is common.

Citations

Citations

U.S. FDA prescribing information for Pramlintide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo